ARWR · Arrowhead Pharmaceuticals, Inc. · Executive Compensation
$41.37
-2.28 (-5.22%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q4 2026 earnings call transcript
Market Cap
$5.85B
Shares
141.37M
Volume · Nov 20
3.91M
Avg daily vol (3M)
2.07M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Christopher Anzalone | President and Chief Executive Officer | $12,423,473 |
| Patrick O’Brien | Chief Operating Officer and General Counsel | $3,933,570 |
| Kenneth A. Myszkowski | Chief Financial Officer | $3,512,376 |
| James Hamilton | Chief of Discovery and Translational Medicine | $3,487,444 |
| Javier San Martin | Former Chief Medical Officer | $3,456,564 |
| Tracie Oliver | Former Chief Commercial Officer | $3,076,780 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Christopher Anzalone | President and Chief Executive Officer | $9,918,093 |
| Patrick O’Brien | Chief Operating Officer and General Counsel | $3,310,337 |
| Kenneth A. Myszkowski | Chief Financial Officer | $3,119,143 |
| Javier San Martin | Former Chief Medical Officer | $3,095,982 |
| James Hamilton | Chief of Discovery and Translational Medicine | $3,046,943 |
| Tracie Oliver | Former Chief Commercial Officer | $873,822 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Christopher Anzalone | President and Chief Executive Officer | $12,031,969 |
| Kenneth A. Myszkowski | Chief Financial Officer | $4,739,552 |
| Patrick O’Brien | Chief Operating Officer and General Counsel | $4,727,863 |
| James Hamilton | Chief of Discovery and Translational Medicine | $4,323,314 |
| Tracie Oliver | Former Chief Commercial Officer | $2,744,471 |
| Javier San Martin | Former Chief Medical Officer | $704,744 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Christopher Anzalone | President and Chief Executive Officer | $24,703,855 |
| Patrick O’Brien | Chief Operating Officer and General Counsel | $5,336,926 |
| Kenneth A. Myszkowski | Chief Financial Officer | $5,333,570 |
| James Hamilton | Chief of Discovery and Translational Medicine | $4,509,947 |
| Javier San Martin | Chief Medical Officer | $644,746 |
| Tracie Oliver | Chief Commercial Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Bruce Given | COO | $16,343,808 |
| Bruce Given, M.D. | Former Chief Operating Officer | $16,343,808 |
| Christopher Anzalone | President and Chief Executive Officer | $14,294,517 |
| James Hassard | Chief Commercial Officer | $7,918,296 |
| Javier San Martin | Chief Medical Officer | $7,899,071 |
| Curt Bradshaw | Former Chief Scientific Officer | $6,373,206 |
| Kenneth A. Myszkowski | Chief Financial Officer | $6,081,852 |
| Patrick O’Brien | Chief Operating Officer and General Counsel | $5,123,502 |
| James Hamilton | Chief of Discovery and Translational Medicine | $3,412,877 |
| Tracie Oliver | Chief Commercial Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Bruce Given, M.D. | Former Chief Operating Officer | $3,958,759 |
| Bruce Given | COO | $3,958,759 |
| James Hassard | Chief Commercial Officer | — |
| Javier San Martin | Chief Medical Officer | — |
| Curt Bradshaw | Former Chief Scientific Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Bruce Given, M.D. | Former Chief Operating Officer | $1,552,061 |
| Bruce Given | COO | $1,552,061 |
| James Hassard | Chief Commercial Officer | — |
| Curt Bradshaw | Former Chief Scientific Officer | — |
| Javier San Martin | Chief Medical Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Matt Cohen, M.D., M.B.A. | director | Appointed | 2026-06-16 |
| Daniel Apel | Chief Financial Officer | Appointed | 2025-04-15 |
|
Ken Myszkowski
“Mr. Myszkowski’s decision to retire was not the result of any disagreement with the Company.”
|
Chief Financial Officer | Retired | 2025-04-15 |
| Douglas Ingram | director | Appointed | 2025-02-07 |
| Douglass Given, M.D., Ph.D. | Chairman of the Board | Retired | 2024-12-18 |
| Hongbo Lu, Ph.D. | independent director | Appointed | 2024-02-22 |
|
Marianne De Backer
“Dr. De Backer's decision to resign was based on her recent appointment as Chief Executive Officer and director of Vir Biotechnology, Inc., and did not result from any disagreement with the Company.”
|
director | Resigned | 2023-02-14 |
| Patrick O'Brien | Chief Operating Officer and General Counsel | Appointed | 2022-07-20 |
| Victoria Vakiener | independent director | Appointed | 2022-05-05 |
| James Hassard | Chief Commercial Officer | Terminated | 2021-08-27 |
Leadership
- Christopher Anzalone CEO, Board Member
- Daniel Apel CFO
- Patrick O'Brien COO
- Patrick O’Brien COO, General Counsel
- Douglas Ingram Board Member
- Dr. Matt Cohen, M.D., M.B.A. Board Member
- Hongbo Lu Board Member
- Hongbo Lu, Ph.D. Board Member
- Oye Olukotun, M.D., MPH Board Member
- Victoria Vakiener Board Member
Key facts
CIK
879407
CUSIP
04280A100
13F (30d)
467 filings
442 filers
Visit website
Investor relations